bearish
Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
152 Views14 Sep 2017 07:49
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Pelham Smithers Associates
Market Intel on Asian Tech with a Japan focus
Price Chart(Sign Up to Access)
- Daiichi Sankyo (4568) - DS-8201 Moves to Phase 2 for Gastric Cancer27 Nov 2017
- Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 201714 Sep 2017
- Did AstraZeneca Really Bid for Daiichi Sankyo, Did Daiichi Sankyo Really Turn Them Down?04 Sep 2017
- Daiichi Sankyo - Downside Limited from Here24 Feb 2017
x